The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma-Reference-Cited by-同舟云学术

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma

Published:2019-01-28 Issue:4 Volume:68 Page:599-608
ISSN:0340-7004
Container-title:Cancer Immunology, Immunotherapy
language:en
Short-container-title:Cancer Immunol Immunother

Author:

Agdashian David,ElGindi Mei,Xie Changqing,Sandhu Milan,Pratt Drew,Kleiner David E.,Figg William D.,Rytlewski Julie A.,Sanders Catherine,Yusko Erik C.,Wood Bradford,Venzon David,Brar Gagandeep,Duffy Austin G.,Greten Tim F.^ORCID,Korangy Firouzeh

Funder

National Cancer Institute

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Immunology,Immunology and Allergy

Link

http://link.springer.com/article/10.1007/s00262-019-02299-8/fulltext.html

Reference20 articles.

1. Greten TF, Sangro B (2018) Targets for immunotherapy of liver cancer. J Hepatol 68:157–166. https://doi.org/10.1016/j.jhep.2017.09.007

2. El-Khoueiry AB, Sangro B, Yau T et al (2017) Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:2492–2502. https://doi.org/10.1016/S0140-6736(17)31046-2

3. Zhu AX, Finn RS, Edeline J et al (2018) Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(18)30351-6

4. Duffy AG, Ulahannan SV, Makorova-Rusher O et al (2017) Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 66:545–551. https://doi.org/10.1016/j.jhep.2016.10.029

5. El-Khoueiry AB, Melero I, Yau T et al (2018) Impact of antitumor activity on survival outcomes, and nonconventional benefit, with nivolumab (NIVO) in patients with advanced hepatocellular carcinoma (aHCC): subanalyses of CheckMate-040. J Clin Oncol 36(suppl 4S–abstract):475

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Editorial: Immune cell development and differentiation in liver diseases;Frontiers in Cell and Developmental Biology;2024-08-21

2. Yttrium-90 Induces an Effector Memory Response with Neoantigen Clonotype Expansion: Implications for Immunotherapy;Cancer Research Communications;2024-08-01

3. Liver Resection and Transplantation in the Era of Checkpoint Inhibitors;JHEP Reports;2024-08

4. Harnessing CD8⁺ T cell dynamics in hepatitis B virus‐associated liver diseases: Insights, therapies and future directions;Clinical and Translational Medicine;2024-06-27

5. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma and Their Hepatic-Related Side Effects: A Review;Cancers;2024-05-28